Mentice

Mentice Rule of 40

The Rule of 40 of Mentice (MNTC.ST) as of Nov 19, 2026 is -15.72 %. In the previous year, Rule of 40 was 1.84 % — a change of -953.86% (lower).

Rule of 40

-15.72 %

YoY

-953.86%

Last updated:

Rule of 40 of Mentice is 2025 -15.72 % . Rule of 40 of Mentice was 2024 1.84 % . It decreases by -953.86% lower compared to the previous year.

The Mentice Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
54.40 SEK
Jan 1, 2019
-23.51 SEK
Jan 1, 2020
-30.92 SEK
Jan 1, 2021
23.38 SEK
Jan 1, 2022
7.37 SEK
Jan 1, 2023
25.29 SEK
Jan 1, 2024
1.84 SEK
Jan 1, 2025
-15.72 SEK
The Mentice Rule of 40 history
YEARRule of 40YoY
-15.72 %-953.86%
1.84 %-92.72%
25.29 %+243.01%
7.37 %-68.47%
23.38 %-175.63%
-30.92 %+31.53%
-23.51 %-143.21%
54.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mentice Stock analysis

What does Mentice do? Mentice AB provides software and hardware simulation solutions for endovascular therapies, targeting healthcare professionals and the medical device industry. The company's solutions are scientifically validated and designed to help users acquire, retain, and enhance procedural skills in neurovascular, cardiovascular, and peripheral interventions. Mentice AB generates revenue through the sale of its simulation products and related services, with key buyers including healthcare providers and medical device manufacturers. The company operates globally, serving clients across multiple healthcare segments that require advanced training tools for minimally invasive procedures. Mentice AB's business model focuses on delivering scientifically validated simulation tools that address skill development needs in complex medical procedures. The firm's product offerings cater to both healthcare institutions seeking to train staff and medical device companies requiring validation tools for their products. By specializing in endovascular therapy simulations, Mentice AB serves a niche market with high demand for precise procedural training solutions. The company's global presence allows it to reach clients in various regions seeking advanced medical simulation technology. The company's revenue streams come from the sale of simulation software and hardware systems alongside ongoing service contracts. Healthcare providers purchase these solutions to improve staff competency in endovascular procedures, while medical device manufacturers use them to validate device performance in simulated environments. Mentice AB's solutions are specifically developed for the medical device industry and healthcare providers, creating a dual revenue stream from both sectors. The firm's focus on scientifically validated tools ensures strong market positioning within specialized medical training segments. Mentice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mentice stock

Rule of 40 of Mentice is -15.72 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Mentice since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Mentice

All Key Metrics — Mentice